Citizen Petition Reform Under Consideration By FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA Chief Counsel Bradshaw says options include creating a two-track process – under which ANDAs could be approved while petitions are still under review – or declaring some petitions frivolous.